James Molloy

Managing Director, Equity Research, Biotechnology & Specialty Pharmaceuticals

James Molloy is a Managing Director and Biotechnology and Specialty Pharmaceuticals Equity Research Analyst at A.G.P./Alliance Global Partners. He provides coverage of companies in several therapeutic categories in the biotechnology & pharmaceuticals sector, with a focus on immuno-oncology, central nervous system, cardiovascular, and anti-infective disorders. Prior to A.G.P., Mr. Molloy was a Managing Director, Biotechnology and Specialty Pharmaceuticals Equity Research Analyst at Laidlaw Capital Markets, Janney Montgomery Scott, and ThinkEquity Partners, and a Vice President of Equity Research at Oppenheimer and Company. Mr. Molloy has almost two decades of experience as a Senior Analyst covering both the mid-capitalization and emerging biotechnology and pharmaceutical sectors. Mr. Molloy began his career as one of the first three analysts at Leerink Partners in Boston. He earned an MBA from the FW Olin Graduate School of Business at Babson College, and a BA from the University of Colorado, Boulder, Colorado.